Search results
Jun 21, 2024 · BOSTON--(BUSINESS WIRE)--Jun. 21, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events ...
Jun 23, 2023 · Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions. – All six patients treated with VX-880 engrafted islet cells, produced endogenous insulin (C-peptide) and had improved glycemic control while reducing or eliminating insulin use –.
Oct 3, 2023 · About the VX-880 Phase 1/2 Clinical Trial. The clinical trial is a Phase 1/2, multi-center, single-arm, open-label study in patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. This study is designed as a sequential, multi-part clinical trial to evaluate the safety and efficacy of VX-880.
Jun 21, 2024 · Researchers say the study marks a promising approach that could one day relieve some people with type 1 diabetes of the need for daily insulin injections.
Oct 18, 2021 · Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes. - First patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal ...
Oct 19, 2021 · Vertex’s Stem Cell Therapy for Diabetes Cure. On Monday, Vertex Pharmaceuticals announced that the first Type 1 diabetes (T1D) patient to be dosed in the Phase I/II clinical trial of its investigational stem cell-derived therapy, VX-880, saw their need for insulin disappear almost entirely, marking a great stride in finding a cure for the ...
May 31, 2022 · BOSTON --(BUSINESS WIRE)--May 31, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell‑derived, fully differentiated...
Jun 24, 2024 · Vertex Pharmaceuticals has presented positive data from its ongoing Phase I/II clinical trial of VX-880 for the treatment of T1D. VX-880 is an investigational stem cell-derived, fully...
May 2, 2022 · BOSTON-- ( BUSINESS WIRE )-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully...
It is being evaluated for patients who have type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 is being investigated as an infusion into the hepatic portal vein and requires immunosuppressive therapy to protect the islet cells from immune rejection.
